Group BMaLfOaOMBS. Multicenter, placebo-controlled trial of lorcaserin for weight management

Translational Research Institute for Metabolism and Diabetes, Florida Hospital and the Sanford-Burnham Institute, Winter Park, FL 32789, USA.
New England Journal of Medicine (Impact Factor: 54.42). 07/2010; 363(3):245-56. DOI: 10.1056/NEJMoa0909809
Source: PubMed

ABSTRACT Lorcaserin is a selective serotonin 2C receptor agonist that could be useful in reducing body weight.
In this double-blind clinical trial, we randomly assigned 3182 obese or overweight adults (mean body-mass index [the weight in kilograms divided by the square of the height in meters] of 36.2) to receive lorcaserin at a dose of 10 mg, or placebo, twice daily for 52 weeks. All patients also underwent diet and exercise counseling. At week 52, patients in the placebo group continued to receive placebo but patients in the lorcaserin group were randomly reassigned to receive either placebo or lorcaserin. Primary outcomes were weight loss at 1 year and maintenance of weight loss at 2 years. Serial echocardiography was used to identify patients in whom valvulopathy (as defined by the Food and Drug Administration) developed.
At 1 year, 55.4% of patients (883 of 1595) receiving lorcaserin and 45.1% of patients (716 of 1587) receiving placebo remained in the trial; 1553 patients continued into year 2. At 1 year, 47.5% of patients in the lorcaserin group and 20.3% in the placebo group had lost 5% or more of their body weight (P<0.001), corresponding to an average loss of 5.8+/-0.2 kg with lorcaserin and 2.2+/-0.1 kg with placebo during year 1 (P<0.001). Among the patients who received lorcaserin during year 1 and who had lost 5% or more of their baseline weight at 1 year, the loss was maintained in more patients who continued to receive lorcaserin during year 2 (67.9%) than in patients who received placebo during year 2 (50.3%, P<0.001). Among 2472 patients evaluated at 1 year and 1127 evaluated at 2 years, the rate of cardiac valvulopathy was not increased with the use of lorcaserin. Among the most frequent adverse events reported with lorcaserin were headache, dizziness, and nausea. The rates of serious adverse events in the two groups were similar.
In conjunction with behavioral modification, lorcaserin was associated with significant weight loss and improved maintenance of weight loss, as compared with placebo. (Funded by Arena Pharmaceuticals; number, NCT00395135.)

Download full-text


Available from: Emil Chuang, Aug 13, 2015
1 Follower
  • Source
    • "Drug Reference N ( T2D ) BMI ( mean ) Age ( mean ) 1 - year ∆%WL ( mean ) % with >5% WL ( versus placebo ) Frequent side effects Uncommon side effects Lorcaserin [ Smith et al . 2010 ] ( BLOOM ) 3182 ( 0 ) 36 . 2 44 . 1 3 . 7% 45% versus 20% Dry mouth Fatigue Dizziness Headache Nausea Urinary tract infection Constipation / diarrhoea Hypoglycaemia ( in patients with T2D ) Lorcaserin [ Fidler et al . 2011 ]"
    [Show abstract] [Hide abstract]
    ABSTRACT: Public health initiatives focused on obesity prevention and lifestyle intervention programmes for patients with obesity have struggled to contain the obesity epidemic to date. In recent years, antiobesity drug therapies have had a limited role in clinical treatment algorithms for patients with obesity. Indeed, a number of high-profile antiobesity drug suspensions have markedly impacted upon the landscape of obesity pharmacotherapy. In this review, we discuss the advent of an increasing array of pharmacotherapeutic agents, which are effective both in inducing weight loss and in maintaining weight loss achieved by lifestyle measures. The development of these drugs as antiobesity agents has followed varying paths, ranging from lorcaserin, a selective serotonin agent, exploiting the beneficial central actions of fenfluramine but without the associated systemic side effects, to liraglutide, a gut hormone already used as a glucose-lowering drug but with appetite-suppressant properties, or the novel drug combination of phentermine/topiramate, two 'old' drugs used in lower doses than with previous therapeutic uses, resulting in an additive effect on weight loss and fewer side effects. We summarize the key findings from recent randomized controlled trials of these three drugs. Although these agents lead to clinically important weight loss when used as monotherapy, the use of antiobesity drugs as adjunctive therapy post intensive lifestyle intervention could prove to be the most successful strategy. Moreover, a progressive approach to obesity pharmacotherapy perhaps offers the best opportunity to finally address the obesity crisis on a mass scale.
    05/2014; 5(3):135-148. DOI:10.1177/2040622314522848
  • Source
    • "Importantly, recent clinical trials with the selective 5-HT 2C agonist lorcaserin for weight loss have shown that this compound does not produce any hallucinogen-like effects (Smith et al., 2009, 2010). Given the lack of significant neuropsychiatric effects of lorcaserin, it appears highly unlikely that hallucinogen binding to 5-HT 2C receptors contributes to hallucinogenesis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Serotonergic hallucinogens produce profound changes in perception, mood, and cognition. These drugs include phenylalkylamines such as mescaline and 2,5-dimethoxy-4-methylamphetamine (DOM), and indoleamines such as (+)-lysergic acid diethylamide (LSD) and psilocybin. Despite their differences in chemical structure, the two classes of hallucinogens produce remarkably similar subjective effects in humans, and induce cross-tolerance. The phenylalkylamine hallucinogens are selective 5-HT(2) receptor agonists, whereas the indoleamines are relatively non-selective for serotonin (5-HT) receptors. There is extensive evidence, from both animal and human studies, that the characteristic effects of hallucinogens are mediated by interactions with the 5-HT(2A) receptor. Nevertheless, there is also evidence that interactions with other receptor sites contribute to the psychopharmacological and behavioral effects of the indoleamine hallucinogens. This article reviews the evidence demonstrating that the effects of indoleamine hallucinogens in a variety of animal behavioral paradigms are mediated by both 5-HT(2) and non-5-HT(2) receptors.
    Neuropharmacology 09/2011; 61(3):364-81. DOI:10.1016/j.neuropharm.2011.01.017 · 4.82 Impact Factor
  • Source
    • "Serotonin (5-hydroxytriptamine, 5-HT) is a neurotransmitter that regulates food intake, energy expenditure, and glucose homeostasis via actions within the central nervous system (Giorgetti and Tecott, 2004; Heisler et al., 2003). Compounds that stimulate the release and/ or inhibit the reuptake of 5-HT are potential pharmaceutical targets for the treatment of obesity (Halford et al., 2010; Smith et al., 2010). Indeed, d-fenfluramine (d-Fen) in combination with phenteramine (Fen/Phen) was widely prescribed and was clinically effective to combat obesity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Serotonin 2C receptors (5-HT(2C)Rs) expressed by pro-opiomelanocortin (POMC) neurons of hypothalamic arcuate nucleus regulate food intake, energy homeostasis and glucose metabolism. However, the cellular mechanisms underlying the effects of 5-HT to regulate POMC neuronal activity via 5-HT(2C)Rs have not yet been identified. In the present study, we found the putative transient receptor potential C (TRPC) channels mediate the activation of a subpopulation of POMC neurons by mCPP (a 5-HT(2C)R agonist). Interestingly, mCPP-activated POMC neurons were found to be a distinct population from those activated by leptin. Together, our data suggest that 5-HT(2C)R and leptin receptors are expressed by distinct subpopulations of arcuate POMC neurons and that both 5-HT and leptin exert their actions in POMC neurons via TRPC channels. VIDEO ABSTRACT:
    Neuron 08/2011; 71(3):488-97. DOI:10.1016/j.neuron.2011.06.012 · 15.98 Impact Factor
Show more